
|Videos|August 30, 2022
Comparing Approved Options for Androgen Inhibition in the mCSPC Setting
Author(s)Marc Matrana, MD
Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Improving Survival, Quality of Life, and Cost-Effectiveness for Allo-HCT
2
FDA Approves SimpleScreen Blood Test for CRC Screening
3
Behind the Gedatolisib FDA Approval: An Investigator's Perspective on HR+ Breast Cancer
4
Emavusertib/Ibrutinib Combo Shows Deepening Responses in PCNSL
5























